louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04272619: Liver Cancer Community Education
Official title: LIVE-R Life: Liver Cancer Education
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Liver Cancer
Keywords: prevention
education
Lead sponsor: Fox Chase Cancer Center
Sponsor class: OTHER
Collaborators: name: Pennsylvania Department of Health
First posted: 2020-02-17
Enrollment: 67
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: This study proposes to bridge the gap between evidence and action and combat rising liver cancer rates attributed to Hepatitis B and C infection in Philadelphia by identifying neighborhoods with higher than expected rates of liver cancer and related risk factors and administering an educational intervention about liver cancer and neighborhood health in those communities, working with existing community partners at Fox Chase Cancer Center.


Eligibility criteria: Inclusion Criteria:

* Speaks/reads English
* Lives in Philadelphia or receives healthcare at a community partner site in Philadelphia

Exclusion Criteria:

* None

Primary outcomes:
measure: Change in Mean Liver Cancer Knowledge
timeFrame: Baseline, 30 minutes
measure: Change in General Interest in Learning About Neighborhood Health
timeFrame: Baseline, 30 minutes
measure: Change in Interest in Learning About Neighborhood Health From a Healthcare Provider
timeFrame: Baseline, 30 minutes
measure: Change in Interest in Learning About Neighborhood Health From Other Sources
timeFrame: Baseline, 30 minutes
measure: Change in Interest in Discussing High Liver Cancer Risk With a Healthcare Provider
timeFrame: Baseline, 30 minutes
measure: Change in Outcome Expectancies for Learning About Neighborhood Health - Patient Behavior
timeFrame: Baseline, 30 minutes
measure: Change in Outcome Expectancies for Learning About Neighborhood Health - Provider Behavior
timeFrame: Baseline, 30 minutes
measure: Change in Intentions About Communicating With Healthcare Provider - Neighborhood Prevalence of Liver Cancer
timeFrame: Baseline, 30 minutes
measure: Change in Intentions About Communicating With Healthcare Provider - Liver Cancer Screening
timeFrame: Baseline, 30 minutes
measure: Change in Intentions About Communicating With Healthcare Provider - Liver Cancer Risk
timeFrame: Baseline, 30 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Fox Chase Cancer Center
state: Pennsylvania
Study officials:
References:
Clinical trial NCT05538741: Hypotension After Anesthetic Induction with Remimazolam in Elderly
Official title: Comparison of the Incidence of Hypotension with Bolus Versus Continuous Remimazolam for Anesthetic Induction in Elderly Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hypotension
Lead sponsor: Kangbuk Samsung Hospital
Sponsor class: OTHER
First posted: 2022-09-14
Enrollment: 62
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Even though remimazolam is known to be safely administered without hemodynamic instability, hypotension is the one of the common side effects of remimazolam. Because elderly patients are susceptible to hypotension due to old age, multimodality, and multiple medications, hypotension can be harmful in elderly patients. Remimazolam can be administered either bolus or continuous for anesthetic induction. In our study the investigators aimed to compare the incidence of hypotension after anesthetic induction using remimazolam by bolus injection and continuous infusion in elderly patients.


Eligibility criteria: Inclusion Criteria:

* Elderly patients with age over 60 years old
* scheduled for elective surgery under general anesthesia
* American Society of Anesthesiology Physical Status I-III

Exclusion Criteria:

* Arrhythmia
* Liver dysfunction
* Kidney dysfunction
* Uncontrolled hypertension
* Uncontrolled diabetes mellitus
* Allergic to benzodiazepines
* Heart failure
* Drug intoxication
* Alcoholics
* Cognitive dysfunction
* Unable to understand and consent voluntarily

Primary outcomes:
measure: The incidence of hypotension
timeFrame: 10 minutes after intubation
Secondary outcomes:
measure: The incidence of bradycardia
timeFrame: 10 minutes after intubation
measure: Number of participants with use of any vasopressors
timeFrame: 10 minutes after intubation
measure: Lowest systolic blood pressure
timeFrame: 10 minutes after intubation
measure: Time to loss of consciousness
timeFrame: 10 minutes after intubation
measure: Total remimazolam used for anesthetic induction
timeFrame: 10 minutes after intubation
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Kangbuk Samsung Hospital
Study officials:
affiliation: Assistant Professor
name: Eunah Cho, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02046941: Brain Biomarkers of Response to Treatment for Apraxia of Speech
Official title: Brain Biomarkers of Response to Treatment for Apraxia of Speech
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Aphasia
Stroke
Keywords: aphasia
stroke
Magnetic Resonance Imaging
Diffusion Magnetic Resonance Imaging
Lead sponsor: VA Office of Research and Development
Sponsor class: FED
First posted: 2014-01-28
Enrollment: 17
Sex: ALL
Minimum age (years): 40
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: The study will use MRI brain imaging to identify brain changes associated in stroke patients after they receive speech-language treatment for their speech difficulties.

Detailed description: The goals of the current study are to identify grey and white matter regions that are predictive of speech treatment response and measure neural plasticity in response to speech treatment, using state-of-the-art neuroimaging and statistical processing techniques in a group of well-characterized left hemisphere patients meeting strict inclusionary criteria. Specifically, the investigators will use voxel-based lesion symptom mapping to identify lesion sites most predictive of a positive response to speech treatment and advanced diffusion imaging techniques to map changes in the integrity of white matter tracts from pre- to post-treatment.

Eligibility criteria: Inclusion Criteria:

* Inclusion criteria are age 40-90
* primary English speaker since \< age 5
* a history of a single left hemisphere stroke
* at least 1 year post-stroke
* at least 12 years of education
* pre-morbidly right-handed (Edinburgh Handedness Questionnaire)
* within normal limits on the Test of Non-Verbal Intelligence

Exclusion Criteria:

* Exclusion criteria will include a pre-morbid neurologic or psychiatric history
* history/current substance abuse disorder
* MRI contraindications
* other motor speech disorders (e.g., dysarthria)
* current or recent (\<2 months) speech/language therapy
* prior SPT
* pre-morbid history of speech/language disorders
* significant hearing disabilities (based on a pure-tone audiological screen at 35 dB HL at 500, 1K, and 2K Hz for at least one ear)
* aphasia severity resulting in \<30th percentile performance on the Porch Index of Communicative Ability-R

Primary outcomes:
measure: Change From Baseline in Percent of Trained Items Correctly Repeated
timeFrame: 8 weeks
measure: Change From Baseline in Percent of Untrained Items Correctly Repeated
timeFrame: 8 weeks
Secondary outcomes:
measure: Percentage Change in Fractional Anisotropy (FA)
timeFrame: 8 weeks
Other outcomes:
Locations:
city: Sacramento
country: United States
facility: VA Northern California Health Care System, Mather, CA
state: California
Study officials:
affiliation: VA Northern California Health Care System, Mather, CA
name: Juliana V. Baldo, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00228241: Left Ventricular Function and Remodelling During Permanent Pacing
Official title: Left Ventricular Function and Remodelling During Permanent Pacing
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Sick Sinus Syndrome
AV-Block
Keywords: Sick sinus syndrome
AV-block
Lead sponsor: Aarhus University Hospital Skejby
Sponsor class: OTHER
First posted: 2005-09-28
Enrollment: 100
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: 1. Background - Pacemaker treatment gives asynchronous activation of the heart that often results in decreased heart function and clinical heart failure. New pacemaker types that stimulates both left and right ventricle ( biventricular pacemakers ) is introduced to the treatment of patients with heart failure, decreased left ventricular function and ECG signs with left bundle branch block.
2. Hypothesis - Ventricular pacing results in remodelling of the left ventricle and decreased left ventricular function. Biventricular pacing do not do this. Ventricular pacing results in heart failure and increased wall stress with decreased 6 minutes walk test and increased BNP in blood samples. This is not seen by biventricular pacing.
3. Materials and methods - 3 studies. All patients are examined by echocardiography 2-dimensional, M-mode, 3-dimensional and with tissue harmonic imaging. Study 1) Patients with AV-conduction disorder that needs pacemaker treatment are randomized to DDD-pacemaker or biventricular pacemaker. Study 2) Patients with sick sinus syndrome included in DANPACE are randomized to AAI- or DDD-pacemaker. Study 3 ) Acute study to examine the changes in patients AV-block before DDD-pacemaker implantation and after implantation.


Eligibility criteria: Inclusion Criteria:

* Sick sinus syndrome
* AV-block

Exclusion Criteria:

* Atrial fibrillation
* AMI
* Heart valve disease

Primary outcomes:
measure: 3-dimensional left ventricular ejection fraction
Secondary outcomes:
measure: TDI echo parameters
measure: 6 MHW
measure: NT-proBNP
Other outcomes:
Locations:
city: Aarhus
country: Denmark
facility: Andi Eie Albertsen
Study officials:
affiliation: Physician, Skejby University Hospital
name: Andi Albertsen, MD
role: STUDY_CHAIR
References:
citation: Albertsen AE, Mortensen PT, Jensen HK, Poulsen SH, Egeblad H, Nielsen JC. Adverse effect of right ventricular pacing prevented by biventricular pacing during long-term follow-up: a randomized comparison. Eur J Echocardiogr. 2011 Oct;12(10):767-72. doi: 10.1093/ejechocard/jer136. Epub 2011 Aug 20.
Clinical trial NCT01775241: Sleep Apnoea Syndrome Without Chronic Heart Failure
Official title: Sleep Apnoea Syndrome Without Chronic Heart Failure
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Sleep Apnoea Syndrome
Lead sponsor: RWTH Aachen University
Sponsor class: OTHER
First posted: 2013-01-24
Enrollment: 26
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with or with supected sleep apnoea syndrome

Brief summary: It is the objective of this study to collect scientific data of sleep apnoea syndrome patients´ cardiac and respiratory function by additional sensors.


Eligibility criteria: Inclusion Criteria:

* patients with supected sleep apnoea syndrome and scheduled diagnosis at a sleep laboratory
* male and female patients aged at least 18 years
* persons who understand and follow the instructions of the study staff
* singed informed consent

Exclusion Criteria:

* persons being housed in an institution by court or governmental order
* pregnancy or breastfeeding
* patients who are not able to consent
* acute or chronic inflammations of the external and middle auditory canal
* abnormal anatomic proportionsof the external and middle auditory canal which are pathological or congenital, for example limitation of the auditory canal
* persons in a dependence or in an employment contract to the investigator
* participation in another study at the same time

Primary outcomes:
measure: Data collection
timeFrame: 1 night
Secondary outcomes:
Other outcomes:
Locations:
city: Aachen
country: Germany
facility: Univeristy Hospital Aachen
state: North Rhine Westfalia
Study officials:
References:
Clinical trial NCT00943241: Screening in Myocardial Perfusion Patients
Official title: Screening for Breast Cancer in Patients Undergoing Myocardial Perfusion Imaging
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Breast Cancer
Keywords: Breast
Breast Cancer
MBI
Molecular Breast Imaging
Molecular Imaging
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
Collaborators: name: Gamma Medica-Ideas
First posted: 2009-07-22
Enrollment: 322
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Female subjects who are undergoing Myocardial Perfusion imaging in the Nuclear Cardiology laboratory at the Mayo Clinic in Rochester, MN.

Brief summary: To expand the understanding of the uptake and distribution of Tc-99m sestamibi in the breast in a normal female population undergoing myocardial perfusion imaging using Molecular Breast Imaging (MBI).

Detailed description: You are being asked to take part in this research study because you have been scheduled to have a scan of your heart. The radioactive dye used to image your heart is also taken up by many types of breast cancer. The investigators have developed a new method for detecting breast cancer, called Molecular Breast Imaging that uses this dye.

The purpose of this study is to see how well this new method works in normal subjects with no known breast cancer and to see if we can detect breast cancer at an earlier stage than mammography. As you read this form describing the study, ask any questions you have. Take your time to decide. Feel free to discuss the study with your family, friends, and healthcare provider before you decide. You may stop participating at any time during the study. You may decide not to participate. If so, none of your current benefits or normal health care will be affected in any way. When you feel comfortable that all your questions have been answered, and you wish to take part in this study, sign this form in order to begin your participation. Your signature means you have been told about the study and what the risks are. Your signature on this form also means that you want to take part in this study.

Eligibility criteria: Inclusion Criteria:

* They have had a mammogram at Mayo Clinic Rochester within the last 12 months
* Undergoing myocardial perfusion imaging

Exclusion Criteria:

* They are unable to understand and sign the consent form
* They are physically unable to sit upright and still for 20 minutes
* They have undergone breast surgery or breast biopsy within the last 12 months.
* They have had trauma to the breast tissue or undergone radiation treatment to the breast within the last 12 months.

Primary outcomes:
measure: Biopsy-proven breast cancer
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Deborah J. Rhodes, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04730141: Effect of Mobilization Protocol on Mobilization
Official title: Effect of Mobilization Protocol on Mobilization Start Time and Patient Care Results in Patients Undergoing Abdominal Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Abdominal Surgery
Nursing
Keywords: surgery and mobilization
early mobilization protocol
Lead sponsor: Saglik Bilimleri Universitesi Gulhane Tip Fakultesi
Sponsor class: OTHER
First posted: 2021-01-29
Enrollment: 42
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Intervention model description: quasi-experimental study
Primary purpose: OTHER

Brief summary: The aim of this study is to determine the effect of early mobilization protocol on patients' mobilization status and patient care outcomes in patients who undergo major abdominal surgery. This study is a prospective non-randomized controlled clinical trial.

Detailed description: The study sample consisted of 42 patients, 21 of whom were the control group and 21 were the intervention group, who had undergone major abdominal open surgery between May and September 2019. The routine mobilization follow-up approach of the intensive care unit was applied to the patients in the control group, and the early mobilization protocol developed by using up-to-date guidelines and expert opinions were applied to the patients in the intervention group. In the study, the data of the control group were firstly collected, then the early mobilization protocol was introduced to the patients through the training brochure prepared and then data of the intervention group were collected. In the study, the characteristics of the patients in both groups belonging to the preoperative period, the distance they walked in the 6-minute walking test and the results of the postoperative period were recorded.

Eligibility criteria: Inclusion Criteria:

* To undergo major abdominal open surgery
* ASA \<IV
* Being over the age of 18
* Not having a barrier to communication
* Having agreed to participate in the study

Exclusion Criteria:

* Being diagnosed that may limit mobilization
* Being diagnosed with chronic obstructive pulmonary disease
* ASA IV-V-VI

Primary outcomes:
measure: The effect of mobilization protocol on mobilization start time
timeFrame: first 24 hours postoperatif
measure: Postoperative sleep quality
timeFrame: Postoperative 24th hour
measure: Postoperative patient satisfaction
timeFrame: Postoperative 24th hour
Secondary outcomes:
measure: Postoperative number of steps
timeFrame: The total number of steps taken during the first 24 hours postoperatively
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Fadime
Study officials:
affiliation: Gulhane Hemsirelik Fakultesi
name: Emine Iyiun
role: STUDY_DIRECTOR
References:
Clinical trial NCT05330741: Whole-Body Vibration Versus Gravity Force Stimulation on Postural Stability in Children With Down Syndrome
Official title: Whole-Body Vibration Versus Gravity Force Stimulation on Postural Stability in Children With Down Syndrome
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Down Syndrome
Keywords: Whole-Body Vibration
Gravity Force Stimulation
Biodex Balance System
Down Syndrome
Lead sponsor: Beni-Suef University
Sponsor class: OTHER
First posted: 2022-04-15
Enrollment: 60
Sex: ALL
Minimum age (years): 8
Maximum age (years): 10
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Designed Physical Therapy program, Whole Body Vibration and, Gravity Force Stimulation
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to compare the effect between of whole-body vibration and gravity force stimulation on postural stability in children with Down syndrome.

Detailed description: Down Syndrome (DS) is one of genetic disorders characterized by some common clinical and functional features. Most children with Down syndrome have deficits in postural stability or balance, co-ordination, gait, and functional mobility throughout childhood and adulthood. Postural control dysfunctions are the most common problems found in children with DS leads them to be more inactive, which contributes to functional mobility problems. Several techniques that involve proprioceptive, vestibular, and visual inputs are so beneficial to children with DS. Whole-body vibration (WBV) is one of the training methods that use high-frequency mechanical stimuli generated by a vibrating platform and transmitted through the body, leading to bone loading and sensory receptor stimulation. Gravity force stimulation (GFS) has a strong impact on the child's sensory system helping to normalize the system through exercises that send strong messages to the brain to regulate the tactile, proprioceptive and vestibular components. Hence, there is need to compare between the effects of whole-body vibration training and gravity force stimulation on postural stability in children with Down syndrome.

Eligibility criteria: Inclusion Criteria:

1. Children ages will be ranged from 8 to 10 years old.
2. Functional hearing and vision.
3. Mild and moderate mental retardation with IQ level (50-70) determined by a psychiatric specialist in the school (IQ measured by Stanford-Binet intelligence scale)
4. Independent standing and walking.

Exclusion Criteria:

1. Synptomatic pain.
2. Musculoskeletal problems or/ atlanto-axial instability.
3. Rheumatic and congenital heart disease
4. History of previous surgical operation
5. Regular participation in any sport activities.

Primary outcomes:
measure: Postural Stability
timeFrame: Up to 12 weeks
Secondary outcomes:
measure: Functional Mobility
timeFrame: Up to 12 weeks
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01307241: RFC and MTHFR SNPs & hENT1- dCK Expression as Prognostic Factors in ALL & hENT1- dCK Expression as Prognostic Factors in AML
Official title: Evaluation of RFC Transporter & MTHFR SNP's, as Well as hEN1 and DCK Expression as Prognostic Factors in Patients With Acute Lymphoblastic Leukemia.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Acute Lymphoblastic Leukemia.
Acute Myeloblastic Leukemia
Keywords: Acute lymphoblastic leukemia
prognostic factor
pharmacogenetics.
Lead sponsor: National Institute of Cancerología
Sponsor class: OTHER_GOV
First posted: 2011-03-02
Enrollment: 50
Sex: ALL
Minimum age (years): 15
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with acute lymphoblastic leukemia

Brief summary: Results of actual treatment in ALL are not optimal. New prognostic factors, which may determine clinical \& molecular response are required. Hyper-CVAD is an internationally accepted schema for such patients. The objective of this pilot study is to evaluate polymorphisms regarding RFC (reduced folate carrier) and MTHFR enzyme, which may affect the function of these proteins, and therefore the intracellular bioavailability of methotrexate. Also, the expression levels of hENT1 and dCK will be evaluated, since such genes codify for citarabine intracellular transport and activation, respectively. Clinical characteristics will be tabulated and analyzed for responders \& non-responders patients. Uni- \& multivariate analysis will be done to evaluate factors influencing on response and survival.


Eligibility criteria: Inclusion Criteria:

* Age: older than 15 years.
* Male, female.
* Normal renal \& liver functions.
* Without previous treatment.
* Candidate to be treated with hyperCVAD Schema (ALL patients).
* Candidate to receive induction remission with cytarabine (AML patients)

Exclusion Criteria:

* Patients not candidate to receive methotrexate or cytarabine.

Primary outcomes:
measure: To evaluate clinical response
timeFrame: December 2012
measure: Clinical responses in relation with SNP's or gene expression
timeFrame: clinical response.
Secondary outcomes:
Other outcomes:
Locations:
city: Mexico city
country: Mexico
facility: Instituto Nacional de Cancerologia
state: DF
Study officials:
affiliation: Instituto Nacional de Cancerología Mexico
name: myrna candelaria, md
role: PRINCIPAL_INVESTIGATOR
References: